SR biotek（A270210）株式概要韓国でスキンケア製品の研究、開発、製造、販売を行っている。 詳細A270210 ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析財務データは報告されていない 意味のある時価総額がありません ( ₩19B )すべてのリスクチェックを見るA270210 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW492,148 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA492,148 investors already sharing narrativesYour Fair Value₩Current Price₩11.47k該当なし内在価値ディスカウントEst. Revenue$PastFuture012016201920222025202620282031Revenue ₩1.0Earnings ₩0.1AdvancedSet Fair ValueView all narrativesSR biotek Inc. 競合他社Csa CosmicSymbol: KOSDAQ:A083660Market cap: ₩24.1bBeauty SkinSymbol: KOSDAQ:A406820Market cap: ₩21.9bKODISymbol: KOSDAQ:A080530Market cap: ₩25.6bHurumSymbol: KOSDAQ:A353190Market cap: ₩20.8b価格と性能株価の高値、安値、推移の概要SR biotek過去の株価現在の株価₩11,470.0052週高値₩37,950.0052週安値₩8,010.00ベータ01ヶ月の変化15.05%3ヶ月変化-37.12%1年変化-56.72%3年間の変化139.46%5年間の変化94.08%IPOからの変化-54.12%最新ニュースNew Risk • Jun 26New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₩14.7b (US$9.55m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Market cap is less than US$10m (₩14.7b market cap, or US$9.55m).お知らせ • Mar 10SR biotek Inc., Annual General Meeting, Mar 24, 2026SR biotek Inc., Annual General Meeting, Mar 24, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 484, dunchon-daero, jungwon-gu, gyeonggi-do, seongnam South KoreaNew Risk • Nov 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Market cap is less than US$100m (₩28.5b market cap, or US$19.5m).New Risk • Aug 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Market cap is less than US$100m (₩40.4b market cap, or US$29.2m).New Risk • May 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 32% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩41.0b market cap, or US$29.4m).お知らせ • Feb 20SR biotek Inc., Annual General Meeting, Mar 27, 2025SR biotek Inc., Annual General Meeting, Mar 27, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 484, dunchon-daero, jungwon-gu, gyeonggi-do, seongnam South Korea最新情報をもっと見るRecent updatesNew Risk • Jun 26New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₩14.7b (US$9.55m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Market cap is less than US$10m (₩14.7b market cap, or US$9.55m).お知らせ • Mar 10SR biotek Inc., Annual General Meeting, Mar 24, 2026SR biotek Inc., Annual General Meeting, Mar 24, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 484, dunchon-daero, jungwon-gu, gyeonggi-do, seongnam South KoreaNew Risk • Nov 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Market cap is less than US$100m (₩28.5b market cap, or US$19.5m).New Risk • Aug 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Market cap is less than US$100m (₩40.4b market cap, or US$29.2m).New Risk • May 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 32% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩41.0b market cap, or US$29.4m).お知らせ • Feb 20SR biotek Inc., Annual General Meeting, Mar 27, 2025SR biotek Inc., Annual General Meeting, Mar 27, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 484, dunchon-daero, jungwon-gu, gyeonggi-do, seongnam South KoreaNew Risk • Jan 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risk Market cap is less than US$100m (₩36.8b market cap, or US$25.1m).お知らせ • Jun 18SR biotek Inc. announced that it has received KRW 1.65 billion in funding from Craver Corporation and other investorsOn June 17, 2024, SR biotek Inc. closed the transaction.お知らせ • Nov 22SR biotek Inc. announced that it expects to receive KRW 443.8467 million in fundingSR biotek Inc. announced a private placement of 134,499 common shares at an issue price of KRW 3,300 per share for gross proceeds of KRW 443,846,700 on November 21, 2022. The transaction will include participation from Craver Corporation Co., Ltd. for 116,399 shares, individual investors, Byeongho Song for 15,768 shares and Hong-gun Yoon for 2,332 shares. The common shares will have a lock-up period of one year. The transaction has been approved by board of directors of the company. The expected date of payment is December 6, 2022.お知らせ • Mar 18SR biotek Inc., Annual General Meeting, Mar 31, 2021SR biotek Inc., Annual General Meeting, Mar 31, 2021, at 09:00 Korea Standard Time.Is New 90 Day High Low • Feb 25New 90-day low: ₩6,010The company is down 24% from its price of ₩7,870 on 27 November 2020. The South Korean market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 10.0% over the same period.Is New 90 Day High Low • Feb 04New 90-day high: ₩9,420The company is up 52% from its price of ₩6,200 on 06 November 2020. The South Korean market is up 27% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is up 16% over the same period.Is New 90 Day High Low • Jan 05New 90-day high: ₩8,400The company is up 6.0% from its price of ₩7,890 on 07 October 2020. The South Korean market is up 23% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 9.0% over the same period.Is New 90 Day High Low • Nov 05New 90-day low: ₩5,900The company is down 26% from its price of ₩8,000 on 07 August 2020. The South Korean market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is flat over the same period.株主還元A270210KR Personal ProductsKR 市場7D-18.9%-2.1%-10.6%1Y-56.7%1.0%76.1%株主還元を見る業界別リターン: A270210過去 1 年間で1 % の収益を上げたKR Personal Products業界を下回りました。リターン対市場: A270210は、過去 1 年間で76.1 % のリターンを上げたKR市場を下回りました。価格変動Is A270210's price volatile compared to industry and market?A270210 volatilityA270210 Average Weekly Movement12.9%Personal Products Industry Average Movement9.0%Market Average Movement9.6%10% most volatile stocks in KR Market17.2%10% least volatile stocks in KR Market5.0%安定した株価: A270210 、 KR市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: A270210の 週次ボラティリティ ( 13% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2005n/an/asrbiotek.com韓国でスキンケア製品の研究、開発、製造、販売を行っている。同社は、健康な肌のために使用される極細針状構造のバイオ素材RAPHITOXを提供している。また、皮膚栄養クリーム、アンチエイジングケアクリーム、皮膚回復製品、オイルディープクレンザー、ジェルクレンザー、エッセンストナー、ナチュラルビタセラム、クーリングマスク、デイリーモイスチャークリーム、インテンスクリーム、トリートメントマスク、フォームクレンザー、皮脂コントロール製品、美白・保湿ケア製品、アロエスージングジェルなども提供している。SR biotek Inc.は2005年に設立され、韓国の城南に本社を置いている。もっと見るSR biotek Inc. 基礎のまとめSR biotek の収益と売上を時価総額と比較するとどうか。A270210 基礎統計学時価総額₩19.09b収益（TTM）₩0売上高(TTM)n/an/aPER（株価収益率n/aP/SレシオA270210 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計A270210 損益計算書（TTM）収益₩0売上原価₩0売上総利益₩0その他の費用₩0収益₩0直近の収益報告該当なし次回決算日該当なし一株当たり利益（EPS）0グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率0.0%A270210 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/29 21:49終値2026/07/29 00:00収益N/A年間収益N/Aデータソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋SR biotek Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Seong Man YooHyundai Motor Securities Co. Ltd.
New Risk • Jun 26New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₩14.7b (US$9.55m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Market cap is less than US$10m (₩14.7b market cap, or US$9.55m).
お知らせ • Mar 10SR biotek Inc., Annual General Meeting, Mar 24, 2026SR biotek Inc., Annual General Meeting, Mar 24, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 484, dunchon-daero, jungwon-gu, gyeonggi-do, seongnam South Korea
New Risk • Nov 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Market cap is less than US$100m (₩28.5b market cap, or US$19.5m).
New Risk • Aug 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Market cap is less than US$100m (₩40.4b market cap, or US$29.2m).
New Risk • May 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 32% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩41.0b market cap, or US$29.4m).
お知らせ • Feb 20SR biotek Inc., Annual General Meeting, Mar 27, 2025SR biotek Inc., Annual General Meeting, Mar 27, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 484, dunchon-daero, jungwon-gu, gyeonggi-do, seongnam South Korea
New Risk • Jun 26New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₩14.7b (US$9.55m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Market cap is less than US$10m (₩14.7b market cap, or US$9.55m).
お知らせ • Mar 10SR biotek Inc., Annual General Meeting, Mar 24, 2026SR biotek Inc., Annual General Meeting, Mar 24, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 484, dunchon-daero, jungwon-gu, gyeonggi-do, seongnam South Korea
New Risk • Nov 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Market cap is less than US$100m (₩28.5b market cap, or US$19.5m).
New Risk • Aug 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Market cap is less than US$100m (₩40.4b market cap, or US$29.2m).
New Risk • May 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 32% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩41.0b market cap, or US$29.4m).
お知らせ • Feb 20SR biotek Inc., Annual General Meeting, Mar 27, 2025SR biotek Inc., Annual General Meeting, Mar 27, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 484, dunchon-daero, jungwon-gu, gyeonggi-do, seongnam South Korea
New Risk • Jan 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risk Market cap is less than US$100m (₩36.8b market cap, or US$25.1m).
お知らせ • Jun 18SR biotek Inc. announced that it has received KRW 1.65 billion in funding from Craver Corporation and other investorsOn June 17, 2024, SR biotek Inc. closed the transaction.
お知らせ • Nov 22SR biotek Inc. announced that it expects to receive KRW 443.8467 million in fundingSR biotek Inc. announced a private placement of 134,499 common shares at an issue price of KRW 3,300 per share for gross proceeds of KRW 443,846,700 on November 21, 2022. The transaction will include participation from Craver Corporation Co., Ltd. for 116,399 shares, individual investors, Byeongho Song for 15,768 shares and Hong-gun Yoon for 2,332 shares. The common shares will have a lock-up period of one year. The transaction has been approved by board of directors of the company. The expected date of payment is December 6, 2022.
お知らせ • Mar 18SR biotek Inc., Annual General Meeting, Mar 31, 2021SR biotek Inc., Annual General Meeting, Mar 31, 2021, at 09:00 Korea Standard Time.
Is New 90 Day High Low • Feb 25New 90-day low: ₩6,010The company is down 24% from its price of ₩7,870 on 27 November 2020. The South Korean market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 10.0% over the same period.
Is New 90 Day High Low • Feb 04New 90-day high: ₩9,420The company is up 52% from its price of ₩6,200 on 06 November 2020. The South Korean market is up 27% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is up 16% over the same period.
Is New 90 Day High Low • Jan 05New 90-day high: ₩8,400The company is up 6.0% from its price of ₩7,890 on 07 October 2020. The South Korean market is up 23% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 9.0% over the same period.
Is New 90 Day High Low • Nov 05New 90-day low: ₩5,900The company is down 26% from its price of ₩8,000 on 07 August 2020. The South Korean market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is flat over the same period.
